Most Popular
Breaking News
Cyagen and Neurophth Enter Global Strategic Collaboration to Develop AI-Designed AAV Gene Therapy Vectors for Ophthalmic Disorders
Nov 08, 2022
Cyagen today announced a strategic collaboration with Neurophth Therapeutics, Inc. to co-develop next-generation AAV gene therapy vectors for specific types of genetic ophthalmic disorders. Read More >
Research Trends
Animal Welfare Focus: Humane Endpoints in Rats and Mice in Tumor Research Programs
Nov 04, 2022
In recent years, more and more people advocate the "3Rs" principle of experimental animals: Reduction, Replacement, and Refinement. Read More >
Newsletter
3rd Annual Gene Therapy for Ophthalmic Disorders Meeting in Review
Oct 31, 2022
Cyagen representatives recently attended The 3rd Annual Gene Therapy for Ophthalmic Disorders meeting with 150+ stakeholders and industry leaders in ophthalmic gene therapy. The event brought together ophthalmology experts with world-class learning tracks to address the challenges faced in the preclinical stages and in clinical development, aiming to get these drugs to the ophthalmic gene therapy patients who need them as fast as possible. Read More >
Research Trends
Vision Stolen by Years - Age-related Macular Degeneration
Oct 26, 2022
Many older adults experience a noticeable loss of vision as age increases, but the inability to see fine details in the center of vision may be a sign of age-related macular degeneration (AMD). Read More >
Research Trends
Accelerating CAR-T Cell Therapy Research
Oct 13, 2022
By using the body's own immune system to kill tumor cells, immune cell therapy is anticipated to be a breakthrough strategy to "cure" many types of cancer. Among them, chimeric antigen receptor T-cell immunotherapy (CAR-T) has achieved remarkable results in the treatment of various hematological malignancies. As of 2022, seven CAR-T cell therapy products have been launched globally, including three in China. Read More >
Research Trends
Research Progress of CAR-T Therapy in Solid Tumor Treatment
Sep 23, 2022
CAR-T cell therapy research has developed rapidly in recent years, largely based on the remarkable efficacy of CAR-T therapy in hematological malignancies, and scientists are moving quickly to apply this innovative immunotherapy to the treatment of solid tumors, including sarcomas, carcinomas, and lymphomas. Herein, we review the background of CAR-T cell therapy in solid tumor treatment, common research targets, CAR-T optimization strategy, and clinical research progress. Read More >
Research Trends
A Study on The Mechanism of Achromatopsia
Sep 15, 2022
Patients with achromatopsia (ACHM) have abnormal color discrimination on the three color vision axes corresponding to the three cone cells. The patient's three cones, which sense red, green and blue, are completely inoperative, so they cannot distinguish between different colors. Read More >
Newsletter
Let's Meet at The 3rd Annual Gene Therapy for Ophthalmic Disorders in September!
Sep 05, 2022
The 3rd Annual Gene Therapy for Ophthalmic Disorders meeting is bringing you even more world class content, bringing you two tracks of learning to tackle the pressing challenges faced in the pre-clinical stages and in clinical development. This includes challenges faces with drug targets including wet AMD, dry AMD, DME, IRDs and more. Read More >
Research Trend
Mechanisms of Angelman Syndrome and Models for Research
Sep 01, 2022
Angelman syndrome (AS) is a rare brain disorder that affects about 1 in 20,000 newborns. Children with AS don't look much different from normal children on the surface—smiling and gentle. However, behind the angelic smile, there are a number of neurodevelopmental problems. The current treatment strategies for Angelman syndrome mainly focus on gene therapy, and the gene delivered by adeno-associated virus (AAV) vector treatment holds promise as a cure for the disease. Read More >
Research Trends
CRISPR-Pro-Mediated Gene Editing System for Effective Treatment of X-linked Retinitis Pigmentosa
Aug 09, 2022
Mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene are associated with X-linked retinitis pigmentosa (XLRP), which accounts for 10% to 20% of all cases of retinitis pigmentosa (RP) and is one of its most severe forms. Herein, we review the research procedure that has culminated in the development of a potential gene therapy for XLRP caused by RPGR mutations. Read More >